Skip to main content
Premium Trial:

Request an Annual Quote

Coming Up - Next Month in GT


Don’t miss these features in the April issue:

Attack on Cancer
In this special issue of Genome Technology, we’ll focus heavily on how the integrated biology arsenal is taking aim at all varieties of cancer, looking at the ways our many technology categories are playing vital roles. From proteomics to bioinformatics, from microarrays to RNAi, from pharmacogenomics to epigenetics, scientists from all avenues of integrated biology are working together in groundbreaking ways to understand, diagnose, and eventually defeat this rampant killer.


Inside the FDA
The FDA has taken center stage for many pharma and even academic researchers in this field. We’ll look at what the agency’s guidelines mean for you, show how they’re affecting the field, and introduce you to the newest FDA honchos who are heading up these initiatives.


Systems biology roundtable
In an attempt to reach some kind of consensus, our experts discuss the basics of systems biology.



The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.